Role of activated renin-angiotensin system in the pathogenesis of diabetic nephropathy

Advances in Pathogenesis of Diabetic Nephropathy

Volumn , Issue , 2011, Pages 161-198

  Kobori, Hiroyuki ^a   Harrison Bernard, Lisa M ^b   Gabriel Navar, L ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873056198     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (245)

1. Joss N, Paterson KR, Deighan CJ, Simpson K, Boulton-Jones JM: Diabetic nephropathy: How effective is treatment in clinical practice? QJM 95: 41-49, 2002
2. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS: Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289: 76-79, 2003
3. Bays HE, Bazata DD, Clark NG, Gavin JR, 3rd, Green AJ, Lewis SJ, Reed ML, Stewart W, Chapman RH, Fox KM, Grandy S: Prevalence of self-reported diagnosis of diabetes mellitus and associated risk factors in a national survey in the US population: SHIELD (study to help improve early evaluation and management of risk factors leading to diabetes). BMC Public Health 7: 277,2007
4. National diabetes information clearinghouse: A service of the NIDDK, NIH. In; 2007.
5. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: Findings from the third national health and nutrition examination survey. JAMA 287: 356-359, 2002
6. Wolf G, Sharma K, Ziyadeh F. Pathophysiology and pathogenesis of diabetic nephropathy. In: Alpern RJ, Hebert SC, eds. Seldin and giebisch's the kidney physiology and pathophysiology. 4th ed. Burlington: Elsevier; 2008:2215-2233.
7. American Society of Nephrology, http://www.Asn-online.Org/facts_and_statistics. In; 2007.
8. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The diabetes control and complications trial research group. N.Engl. J.Med. 329: 977-986, 1993
9. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK prospective diabetes study (UKPDS) group. Lancet 352: 837-853, 1998
10. Schrijvers BF, De Vriese AS, Flyvbjerg A: From hyperglycemia to diabetic kidney disease: The role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr. Rev. 25: 971-1010, 2004
11. Jaimes EA, Hua P, Tian RX, Raij L: Human glomerular endothelium: Interplay among glucose, free fatty acids angiotensin II and oxidative stress in hyperglycemia. Am. J. Physiol. Renal. Physiol. 10.11 52/ajprenal.00248.02009, 2009
12. Taguma Y, Kitamoto Y, Futaki G, Ueda H, Monma H, Ishizaki M, Takahashi H, Sekino H, Sasaki Y: Effect of captopril on heavy proteinuria in azotemic diabetics. N. Engl. J. Med. 313: 1617-1620, 1985
13. Lewis EJ, Hunsicker LG, Bain KP, Rhode RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. 329: 1456-1462, 1993
14. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J.Med. 345: 861-869, 2001
15. Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH: Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int. 63: 1874-1880,2003
16. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. BMJ 321: 1440-1444, 2000
17. Huang XR, Chen WY, Truong LD, Lan HY: Chymase is upregulated in diabetic nephropathy: Implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J. Am. Soc. Nephrol. 14: 1738-1747, 2003
18. Navar LG, Harrison-Bernard LM, Nishiyama A, Kobori H: Regulation of intrarenal angiotensin II in hypertension. Hypertension 39: 316-322, 2002
19. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, Drummond K, Donnelly S, Goodyer P, Gubler MC, Klein R: Renal and retinal effects of enalapril and losartan in type 1 diabetes. N. Engl J Med 361: 40-51, 2009
20. Tamsma JT: Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 361: 1410; author reply 1411,2009
21. Sowers JR, Epstein M, Frohlich ED: Diabetes, hypertension, and cardiovascular disease: An update. Hypertension 37: 1053-1059, 2001
22. Hostetter TH: Diabetic nephropathy. Metabolic versus hemodynamic considerations. Diabetes Care 15: 1205-1215, 1992
23. Vallon V, Richter K, Blantz RC, Thomson S, Osswald H: Glomerular hyperfiltration in experimental diabetes mellitus: Potential role of tubular reabsorption. J. Am. Soc. Nephrol. 10: 2569-2576, 1999
24. Zatz R, Meyer TW, Rennke HG, Brenner BM: Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc. Natl. Acad. Sci. USA 82: 5963-5967, 1985
25. Gurley SB, Clare SE, Snow KP, Hu A, Meyer TW, Coffman TM: Impact of genetic background on nephropathy in diabetic mice. Am. J. Physiol. Renal. Physiol. 290: F214-222, 2006
26. Carmines PK, Ohishi K, Ikenaga H: Functional impairment of renal afferent arteriolar voltage-gated calcium channels in rats with diabetes mellitus. J Glin Invest 98: 2564-2571, 1996
27. Thomson SC, Vallon V, Blantz RC: Kidney function in early diabetes: The tubular hypothesis of glomerular filtration. Am. J. Physiol. Renal. Physiol. 286: F8-15, 2004
28. Ohishi K, Okwueze MI, Vari RC, Carmines PK: Juxtamedullary microvascular dysfunction during the hyperfiltration stage of diabetes mellitus. Am. J. Physiol. 267: F99-105, 1994
29. Ikenaga H, Bast JP, Fallet RW, Carmines PK: Exaggerated impact of ATP-sensitive K(+) channels on afferent arteriolar diameter in diabetes mellitus. J. Am. Soc. Nephrol. 11: 1199-1207, 2000
30. Bank N, Aynedjian HS: Role of EDRF (nitric oxide) in diabetic renal hyperfiltration. Kidney Int. 43: 1306-1312, 1993
31. Komers R, Anderson S: Paradoxes of nitric oxide in the diabetic kidney. Am. J. Physiol. Renal. Physiol. 284: F1121-1137, 2003
32. Sugimoto H, Shikata K, Matsuda M, Kushiro M, Hayashi Y, Hiragushi K, Wada J, Makino H: Increased expression of endothelial cell nitric oxide synthase (ecnos) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy. Diabetologia 41: 1426-1434, 1998
33. Veelken R, Hilgers KF, HartnerA, Haas A, Bohmer KP, Sterzel RB: Nitric oxide synthase isoforms and glomerular hyperfiltration in early diabetic nephropathy. J. Am. Soc. Nephrol. 11: 71-79, 2000
34. Tolins JP, Shultz PJ, Raij L, Brown DM, Mauer SM: Abnormal renal hemodynamic response to reduced renal perfusion pressure in diabetic rats: Role of no. Am. J. Physiol. 265: F886-895, 1993
35. Levine DZ, Iacovitti M, Robertson SJ, Mokhtar GA: Modulation of single-nephron GFR in the db/db mouse model of type 2 diabetes mellitus. Am. J. Physiol. Regul. Integr. Comp. Physiol. 290: R975-981, 2006
36. Bell TD, DiBona GF, Biemiller R, Brands MW: Continuously measured renal blood flow does not increase in diabetes if nitric oxide synthesis is blocked. Am. J. Physiol. Renal. Physiol. 295: F1449-1456, 2008
37. Brands MW, Bell TD, Gibson B: Nitric oxide may prevent hypertension early in diabetes by counteracting renal actions of superoxide. Hypertension 43: 57-63, 2004
38. Ishii N, Patel KP, Lane PH, Taylor T, Bian K, Murad F, Pollock JS, Carmines PK: Nitric oxide synthesis and oxidative stress in the renal cortex of rats with diabetes mellitus. J.Am. Soc. Nephrol. 12: 1630-1639, 2001
39. Komers R, Oyama TT, Chapman JG, Allison KM, Anderson S: Effects of systemic inhibition of neuronal nitric oxide synthase in diabetic rats. Hypertension 35: 655-661, 2000
40. Prabhakar SS: Role of nitric oxide in diabetic nephropathy. Semin Nephrol 24: 333-344, 2004
41. Ohishi K, Carmines PK: Superoxide dismutase restores the influence of nitric oxide on renal arterioles in diabetes mellitus. J.Am. Soc. Nephrol. 5: 1559-1566, 1995
42. PfluegerAC, Larson TS, Hagl S, Knox FG: Role of nitric oxide in intrarenal hemodynamics in experimental diabetes mellitus in rats. Am. J. Physiol. 277: R725-733, 1999
43. Keynan S, Hirshberg B, Levin-Iaina N, Wexler ID, Dahan R, Reinhartz E, Ovadia H, Wollman Y, Chernihovskey T, Iaina A, Raz I: Renal nitric oxide production during the early phase of experimental diabetes mellitus. Kidney Int. 58: 740-747, 2000
44. Schoonmaker GC, Fallet RW, Carmines PK: Superoxide anion curbs nitric oxide modulation of afferent arteriolar ANG II responsiveness in diabetes mellitus. Am. J. Physiol. Renal. Physiol. 278: F302-309, 2000
45. Zhao HJ, Wang S, Cheng H, Zhang MZ, Takahashi T, Fogo AB, Breyer MD, Harris RC: Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J. Am. Soc. Nephrol. 17: 2664-2669, 2006
46. Sochett EB, Cherney DZ, Curtis JR, Dekker MG, Scholey JW, Miller JA: Impact of renin angiotensin system modulation on the hyperfiltration state in type 1 diabetes. J.Am. Soc. Nephrol. 17: 1703-1709, 2006
47. Anderson S, Jung FF, Ingelfinger JR: Renal renin-angiotensin system in diabetes: Functional, immunohistochemical, and molecular biological correlations. Am. J. Physiol. 265: F477-486, 1993
48. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH: Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int. 57: 601-606, 2000
49. Hollenberg NK, Price DA, Fisher ND, Lansang MC, Perkins B, Gordon MS, Williams GH, Laffel LM: Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. Kidney Int. 63: 172-178, 2003
50. Giunti S, Barit D, Cooper ME: Mechanisms of diabetic nephropathy: Role of hypertension. Hypertension 48: 519-526, 2006
51. Mitchell KD, Navar LG. Intrarenal actions of angiotensin II in the pathogenesis of experimental hypertension. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, diagnosis and management. 2nd ed. New York, NY: Raven Press; 1995:1437-1450.
52. Kobori H, Nangaku M, Navar LG, Nishiyama A: The intrarenal renin-angiotensin system: From physiology to the pathobiology of hypertension and kidney disease. Pharmacol. Rev. 59: 251-287, 2007
53. Carey RM, Siragy HM: The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol. Metab. 14: 274-281, 2003
54. Santos RA, Simoese Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R, Walther T: Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor mas. Proc. Natl. Acad. Sci. USA 100: 8258-8263, 2003
55. Navar LG, Prieto-Carrasquero MC, Kobori H. Chapter 1: Molecular aspects of the renal renin-angiotensin system. In: Re RN, DiPette DJ, Schiffrin EL, Sowers JR, eds. Molecular mechanisms in hypertension. 1st ed. Oxfordshire, UK: Taylor and Francis Medical; 2006:3-14.
56. Dzau VJ, Re R: Tissue angiotensin system in cardiovascular medicine. A paradigm shift? Circulation 89: 493-498, 1994
57. Baltatu O, Silva JA, Jr., Ganten D, Bader M: The brain renin-angiotensin system modulates angiotensin II-induced hypertension and cardiac hypertrophy. Hypertension 35: 409-412, 2000
58. Dell'Italia LJ, Meng QC, Balcells E, Wei CC, Palmer R, Hageman GR, Durand J, Hankes GH, Oparil S: Compartmentalization of angiotensin II generation in the dog heart evidence for independent mechanisms in intravascular and interstitial spaces. J. Clin. Invest. 100: 253-258, 1997
59. Mazzocchi G, Malendowicz LK, Markowska A, Albertin G, Nussdorfer GG: Role of adrenal renin-angiotensin system in the control of aldosterone secretion in sodium-restricted rats. Am. J. Physiol. Endocrinol. Metab. 278: E1027-1030, 2000
60. Danser AH, Admiraal PJ, Derkx FH, Schalekamp MA: Angiotensin I-to-II conversion in the human renal vascular bed. J. Hypertens. 16: 2051-2056, 1998
61. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW: Angiotensin II stimulates nadh and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 74: 1141-1148, 1994
62. Ingelfinger JR, Zuo WM, Fon EA, Ellison KE, Dzau VJ: In situ hybridization evidence for angiotensinogen messenger RNA in the rat proximal tubule. An hypothesis for the intrarenal renin angiotensin system. J. Clin. Invest. 85: 417-423, 1990
63. Terada Y, Tomita K, Nonoguchi H, Marumo F: PCR localization of angiotensin II receptor and angiotensinogen mRNAs in rat kidney. Kidney Int. 43: 1251-1259, 1993
64. Richoux JP, Cordonnier JL, Bouhnik J, Clauser E, Corvol P, Menard J, Grignon G: Immunocytochemical localization of angiotensinogen in rat liver and kidney. Cell Tissue Res. 233: 439-451, 1983
65. Darby IA, Congiu M, Fernley RT, Sernia C, Coghlan JP: Cellular and ultrastructural location of angiotensinogen in rat and sheep kidney. Kidney Int. 46: 1557-1560, 1994
66. Darby IA, Sernia C: In situ hybridization and immunohistochemistry of renal angiotensinogen in neonatal and adult rat kidneys. Cell Tissue Res. 281: 197-206, 1995
67. Kobori H, Harrison-Bernard LM, Navar LG: Expression of angiotensinogen mRNA and protein in angiotensin II-dependent hypertension. J. Am. Soc. Nephrol. 12: 431-439, 2001
68. Leyssac PP: Changes in single nephron renin release are mediated by tubular fluid flow rate. Kidney Int. 30: 332-339, 1986
69. Yanagawa N, Capparelli AW, Jo OD, Friedal A, Barrett JD, Eggena P: Production of angiotensinogen and renin-like activity by rabbit proximal tubular cells in culture. Kidney Int. 39: 938-941, 1991
70. Henrich WL, McAllister EA, Eskue A, Miller T, Moe OW: Renin regulation in cultured proximal tubular cells. Hypertension 27: 1337-1340, 1996
71. Moe OW, Ujiie K, Star RA, Miller RT, Widell J, Alpern RJ, Henrich WL: Renin expression in renal proximal tubule. J. Glin. Invest. 91: 774-779, 1993
72. Sibony M, Gasc JM, Soubrier F, Alhenc-Gelas F, Corvol P: Gene expression and tissue localization of the two isoforms of angiotensin I converting enzyme. Hypertension 21: 827-835, 1993
73. Schulz WW, Hagler HK, Buja LM, Erdos EG: Ultrastructural localization of angiotensin I-converting enzyme (EC 3.4.15.1) and neutral metalloendopeptidase (EC 3.4.24.11) in the proximal tubule of the human kidney. Lab. Invest. 59: 789-797, 1988
74. Vio CP, Jeanneret VA: Local induction of angiotensin-converting enzyme in the kidney as a mechanism of progressive renal diseases. Kidney Int. Suppl. S57-63, 2003
75. Casarini DE, Boim MA, Stella RC, Krieger-Azzolini MH, Krieger JE, Schor N: Angiotensin I-converting enzyme activity in tubular fluid along the rat nephron. Am. J. Physiol. 272: F405-409, 1997
76. Kang JJ, Toma I, Sipos A, Meer EJ, Vargas SL, Peti-Peterdi J: The collecting duct is the major source of prorenin in diabetes. Hypertension 51: 1597-1604, 2008
77. Prieto-Carrasquero MC, Botros FT, Pagan J, Kobori H, Seth DM, Casarini DE, Navar LG: Collecting duct renin is upregulated in both kidneys of 2-kidney, 1-clip goldblatt hypertensive rats. Hypertension 51: 1590-1596, 2008
78. Prieto-Carrasquero MC, Kobori H, Ozawa Y, Gutierrez A, Seth D, Navar LG: AT1 receptor-mediated enhancement of collecting duct renin in angiotensin II-dependent hypertensive rats. Am. J. Physiol. Renal. Physiol. 289: F632-637, 2005
79. Rohrwasser A, Morgan T, Dillon HF, Zhao L, Callaway CW, Hillas E, Zhang S, Cheng T, Inagami T, Ward K, Terreros DA, Lalouel JM: Elements of a paracrine tubular renin-angiotensin system along the entire nephron. Hypertension 34: 1265-1274, 1999
80. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD: Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J. Glin. Invest. 109: 1417-1427, 2002
81. Advani A, Kelly DJ, Cox AJ, White KE, Advani SL, Thai K, Connelly KA, Yuen D, Trogadis J, Herzenberg AM, Kuliszewski MA, Leong-Poi H, Gilbert RE: The (pro)renin receptor: Site-specific and functional linkage to the vacuolar H+-atpase in the kidney. Hypertension 54: 261-269, 2009
82. Wang ZQ, Millatt LJ, Heiderstadt NT, Siragy HM, Johns RA, Carey RM: Differential regulation of renal angiotensin subtype AT1A and AT2 receptor protein in rats with angiotensin-dependent hypertension. Hypertension 33: 96-101, 1999
83. Miyata N, Park F, Li XF, Cowley AW, Jr.: Distribution of angiotensin AT1 and AT2 receptor subtypes in the rat kidney. Am. J. Physiol. 277: F437-446, 1999
84. Bouby N, Hus-Citharel A, Marchetti J, Bankir L, Corvol P, Llorens-Cortes C: Expression of type 1 angiotensin II receptor subtypes and angiotensin II-induced calcium mobilization along the rat nephron. J. Am. Soc. Nephrol. 8: 1658-1667, 1997
85. Harrison-Bernard LM, Navar LG, Ho MM, Vinson GP, El-Dahr SS: Immunohistochemical localization of ANG II AT1 receptor in adult rat kidney using a monoclonal antibody. Am. J. Physiol. 273: F170-F177, 1997
86. Anderson S: Physiologic actions and molecular expression of the renin-angiotensin system in the diabetic rat. Miner Electrolyte Metab. 24: 406-411, 1998
87. Harrison-Bernard LM, Imig JD, Carmines PK: Renal AT1 receptor protein expression during the early stage of diabetes mellitus. Int. J. Exp. Diabetes Res. 3: 97-108, 2002
88. Zimpelmann J, Kumar D, Levine DZ, Wehbi G, Imig JD, Navar LG, Burns KD: Early diabetes mellitus stimulates proximal tubule renin mRNA expression in the rat. Kidney Int. 58: 2320-2330, 2000
89. Wehbi GJ, Zimpelmann J, Carey RM, Levine DZ, Burns KD: Early streptozotocin-diabetes mellitus downregulates rat kidney AT2 receptors. Am. J. Physiol. Renal. Physiol. 280: F254-265, 2001
90. Nagai Y, Yao L, Kobori H, Miyata K, Ozawa Y, Miyatake A, Yukimura T, Shokoji T, Kimura S, Kiyomoto H, Kohno M, Abe Y, Nishiyama A: Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J. Am. Soc. Nephrol. 16: 703-711, 2005
91. Nishiyama A, Nakagawa T, Kobori H, Nagai Y, Okada N, Konishi Y, Morikawa T, Okumura M, MedaI, Kiyomoto H, Hosomi N, Mori T, Ito S, Imanishi M: Strict angiotensin blockade prevents the augmentation of intrarenal angiotensin II and podocyte abnormalities in type 2 diabetic rats with microalbuminuria. J. Hypertens. 26: 1849-1859, 2008
92. Suzaki Y, Ozawa Y, Kobori H: Intrarenal oxidative stress and augmented angiotensinogen are precedent to renal injury in Zucker diabetic fatty rats. Int. J. Biol. Sci. 3: 40-46, 2007
93. Miyata K, Ohashi N, Suzaki Y, KatsuradaA, Kobori H: Sequential activation of the reactive oxygen species/angiotensinogen/renin-angiotensin system axis in renal injury of type 2 diabetic rats. Clin. Exp. Pharmacol. Physiol. 35: 922-927, 2008
94. Ichihara A, Hayashi M, Kaneshiro Y, Suzuki F, Nakagawa T, Tada Y, Koura Y, Nishiyama A, Okada H, Uddin MN, Nabi AH, Ishida Y, Inagami T, Saruta T: Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "Handle" Region for nonproteolytic activation of prorenin. J. Glin. Invest. 114: 1128-1135, 2004
95. Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, Webb RL, Mueller DN, Feldt S, Cumin F, Maniara W, Persohn E, Schuetz H, Jan Danser AH, Nguyen G: Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic tg(mren-2)27 rats. Hypertension 52: 130-136, 2008
96. Takahashi H, Ichihara A, Kaneshiro Y, Inomata K, Sakoda M, Takemitsu T, Nishiyama A, Itoh H: Regression of nephropathy developed in diabetes by (pro)renin receptor blockade. J. Am. Soc. Nephrol. 18: 2054-2061, 2007
97. Ichihara A, Sakoda M, Kurauchi-Mito A, Nishiyama A, Itoh H: Involvement of receptor-bound prorenin in development of nephropathy in diabetic db/db mice. J. Am. Soc. Hypertens 2: 332-340, 2008
98. IchiharaA, Suzuki F, Nakagawa T, Kaneshiro Y, Takemitsu T, Sakoda M, Nabi AH, Nishiyama A, Sugaya T, Hayashi M, Inagami T: Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1 a receptor-deficient mice. J. Am. Soc. Nephrol. 17: 1950-1961, 2006
99. Batenburg WW, Jan Danser AH: The (pro)renin receptor: A new addition to the renin-angiotensin system? Eur. J. Pharmacol. 585: 320-324, 2008
100. Wolf G, Ritz E: Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: Pathophysiology and indications. Kidney Int. 67: 799-812, 2005
101. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA: Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc. Natl. Acad. Sci. US A 90: 1814-1818, 1993
102. Teles F, Machado FG, Ventura BH, Malheiros DM, Fujihara CK, Silva LF, Zatz R: Regression of glomerular injury by losartan in experimental diabetic nephropathy. Kidney Int. 75: 72-79, 2009
103. Azizi M, Chatellier G, Guyene TT, Murieta-Geoffroy D, Menard J: Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 92: 825-834, 1995
104. Menard J, Campbell DJ,Azizi M, Gonzales MF: Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats. Circulation 96: 3072-3078, 1997
105. Cohen DL, Townsend RR: Is there added value to adding ARB to ACE inhibitors in the management of CKD? J.Am. Soc. Nephrol. 20: 1666-1668, 2009
106. Skeggs LT, Jr., Kahn JR, Shumway NP: The preparation and function of the hypertensin-converting enzyme. J.Exp. Med. 103: 295-299, 1956
107. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S: A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin Ito angiotensin 1-9. Circ. Res. 87: E1-9, 2000
108. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveira-dosSantos AJ, da Costa J, Zhang L, Pei Y, Scholey J, Ferrario CM, Manoukian AS, Chappell MC, Backx PH, Yagil Y, Penninger JM: Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417: 822-828, 2002
109. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI: Counterregulatory actions of angiotensin-(1-7). Hypertension 30: 535-541, 1997
110. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F,Acton S, Patane M, Nichols A, Tummino P: Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J. Biol. Chem. 277: 14838-14843, 2002
111. Oudit GY, Herzenberg AM, Kassiri Z, Wong D, Reich H, Khokha R, Crackower MA, Backx PH, Penninger JM, Scholey JW: Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am. J. Pathol. 168: 1808-1820, 2006
112. Wong DW, Oudit GY, Reich H, Kassiri Z, Zhou J, Liu QC, Backx PH, Penninger JM, Herzenberg AM, Scholey JW: Loss of angiotensin-converting enzyme-2 (ace2) accelerates diabetic kidney injury. Am. J. Pathol. 171: 438-451, 2007
113. Wysocki J, Ye M, Soler MJ, Gurley SB, Xiao HD, Bernstein KE, Coffman TM, Chen S, Batlle D: ACE and ACE2 activity in diabetic mice. Diabetes 55: 2132-2139, 2006
114. Soler MJ, Wysocki J, Ye M, Lloveras J, Kanwar Y, Batlle D: ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice. Kidney Int. 72: 614-623, 2007
115. Ye M, Wysocki J, Naaz P, Salabat MR, LaPointe MS, Batlle D: Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: A renoprotective combination? Hypertension 43: 1120-1125, 2004
116. Park S, Bivona BJ, Kobori H, Seth DM, Chappell MC, Lazartigues E, Harrison-Bernard LM: Major role for ACE-independent intrarenal ANGII formation in type II diabetes. Am. J. Physiol. Renal. Physiol. 298: F37-F48, 2010
117. Lazartigues E, Feng Y, Lavoie JL: The two faces of the tissue renin-angiotensin systems: Implication in cardiovascular diseases. Curr. Pharm. Des. 13: 1231-1245, 2007
118. Navar LG, Inscho EW, Majid SA, Imig JD, Harrison-Bernard LM, Mitchell KD: Paracrine regulation of the renal microcirculation. Physiol. Rev. 76: 425-536, 1996
119. Navar LG, Imig JD, Zou L, Wang CT: Intrarenal production of angiotensin II. Sem. Nephrol. 17: 412-422, 1997
120. IchiharaA, Kobori H, Nishiyama A, Navar LG: Renal renin-angiotensin system. Contrib. Nephrol. 143: 117-130, 2004
121. Burrell LM, Johnston CI, Tikellis C, Cooper ME: ACE2, a new regulator of the renin-angiotensin system. Trends Endocrinol. Metab. 15: 166-169, 2004
122. Danilczyk U, Penninger JM: Angiotensin-converting enzyme II in the heart and the kidney. Circ Res 98: 463-471, 2006
123. Danilczyk U, Eriksson U, Oudit GY, Penninger JM: Physiological roles of angiotensin-converting enzyme 2. Cell Mol. Life Sci. 61: 2714-2719, 2004
124. Shaltout HA, Westwood B, Averill DB, Ferrario CM, Figueroa J, Diz DI, Rose JC, Chappell MC: Angiotensin metabolism in renal proximal tubules, urine and serum of sheep: Evidence for ACE2-dependent processing of angiotensin II. Am. J. Physiol. Renal. Physiol. 2006
125. Stegbauer J, Vonend O, Oberhauser V, Rump LC: Effects of angiotensin-(1-7) and other bioactive components of the renin-angiotensin system on vascular resistance and noradrenaline release in rat kidney. J.Hypertens 21: 1391-1399, 2003
126. Modrall JG, Sadjadi J, Brosnihan KB, Gallagher PE, Yu CH, Kramer GL, Bernstein KE, Chappell MC: Depletion of tissue angiotensin-converting enzyme differentially influences the intrarenal and urinary expression of angiotensin peptides. Hypertension 43: 849-853, 2004
127. Zhong JC, Huang DY, Yang YM, Li YF, Liu GF, Song XH, Du K: Upregulation of angiotensin-converting enzyme 2 by all-trans retinoic acid in spontaneously hypertensive rats. Hypertension 44: 907-912, 2004
128. Tikellis C, Johnston CI, Forbes JM, Burns WC, Burrell LM, Risvanis J, Cooper ME: Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 41: 392-397, 2003
129. Belova LA: Angiotensin II-generating enzymes. Biochemistry (Mosc) 65: 1337-1345, 2000
130. Urata H, Boehm KD, Philip A, Kinoshita A, Gabrovsek J, Bumpus FM, Husain A: Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J. Clin. Invest. 91: 1269-1281, 1993
131. Miyazaki M, Takai S: Local angiotensin II-generating system in vascular tissues: The roles of chymase. Hypertens. Res. 24: 189-193, 2001
132. Miyazaki M, Takai S: Role of chymase on vascular proliferation. J. Renin. Angiotensin Aldosterone Syst. 1: 23-26, 2000
133. McEuenAR, Sharma B, Walls AF: Regulation of the activity of human chymase during storage and release from mast cells: The contributions of inorganic cations, ph, heparin and histamine. Biochim. Biophys. Acta 1267: 115-121, 1995
134. Takai S, Shiota N, Yamamoto D, Okunishi H, Miyazaki M: Purification and characterization of angiotensin II-generating chymase from hamster cheek pouch. Life Sci. 58: 591-597, 1996
135. Nakano K, Takaishi K, KodamaA, Mammoto A, Shiozaki H, Monden M, Takai Y: Distinct actions and cooperative roles of ROCK and mdia in Rho small G protein-induced reorganization of the actin cytoskeleton in madin-darby canine kidney cells. Mol. Biol. Cell 10: 24812491-1999
136. Guo C, Ju H, Leung D, Massaeli H, Shi M, Rabinovitch M: A novel vascular smooth muscle chymase is upregulated in hypertensive rats. J. Clin. Invest. 107: 703-715, 2001
137. Ju H, Gros R, You X, Tsang S, Husain M, Rabinovitch M: Conditional and targeted overexpression of vascular chymase causes hypertension in transgenic mice. Proc. Natl. Acad. Sci. USA 98: 7469-7474, 2001
138. Akasu M, Urata H, Kinoshita A, Sasaguri M, Ideishi M, Arakawa K: Differences in tissue angiotensin II-forming pathways by species and organs in vitro. Hypertension 32: 514-520, 1998
139. Kishi K, Jin D, Takai S, Muramatsu M, Katayama H, Tamai H, Miyazaki M: Role of chymase-dependent angiotensin II formation in monocrotaline-induced pulmonary hypertensive rats. Pediatr. Res. 60: 77-82, 2006
140. Petrie MC, Padmanabhan N, McDonald JE, Hillier C, Connell JM, McMurray JJ: Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. J. Am. Coll Cardiol. 37: 1056-1061, 2001
141. Wei CC, Tian B, Perry G, Meng QC, Chen YF, Oparil S, Dell'Italia LJ: Differential ANG II generation in plasma and tissue of mice with decreased expression of the ACE gene. Am. J. Physiol. Heart Circ. Physiol. 282: H2254-2258, 2002
142. Murakami M, Matsuda H, Kubota E, Wakino S, Honda M, Hayashi K, Saruta T: Role of angiotensin II generated by angiotensin converting enzyme-independent pathways in canine kidney. Kidney Int. Suppl. 63: S132-135, 1997
143. Tokuyama H, Hayashi K, Matsuda H, Kubota E, Honda M, Okubo K, Takamatsu I, Tatematsu S, Ozawa Y, Wakino S, Saruta T: Differential regulation of elevated renal angiotensin II in chronic renal ischemia. Hypertension 40: 34-40, 2002
144. Sadjadi J, Kramer GL, Yu CH, Burress Welborn M, 3rd, Chappell MC, Gregory Modrall J: Angiotensin converting enzyme-independent angiotensin ii production by chymase is up-regulated in the ischemic kidney in renovascular hypertension. J. Surg. Res. 127: 65-69, 2005
145. Yamada M, Ueda M, Naruko T, Tanabe S, Han YS, Ikura Y, Ogami M, Takai S, Miyazaki M: Mast cell chymase expression and mast cell phenotypes in human rejected kidneys. Kidney Int. 59: 1374-1381, 2001
146. Morikawa T, Imanishi M, Suzuki H, Okada N, Okumura M, Konishi Y, Yoshioka K, Takai S, Miyazaki M: Mast cell chymase in the ischemic kidney of severe unilateral renovascular hypertension. Am. J. Kidney Dis. 45: e45-50, 2005
147. Koka V, Wang W, Huang XR, Kim-Mitsuyama S, Truong LD, Lan HY: Advanced glycation end products activate a chymase-dependent angiotensin II-generating pathway in diabetic complications. Circulation 113: 1353-1360, 2006
148. Ritz E: Chymase: A potential culprit in diabetic nephropathy? JAm Soc Nephrol 14: 1952-1954, 2003
149. Haneda M, Koya D, Kikkawa R: Cellular mechanisms in the development and progression of diabetic nephropathy: Activation of the DAG-PKC-ERK pathway. Am. J. Kidney Dis. 38: S178-181, 2001
150. Kikkawa R, Koya D, Haneda M: Progression of diabetic nephropathy. Am. J. Kidney Di.s 41: S19-21, 2003
151. Park JY, Ha SW, King GL: The role of protein kinase C activation in the pathogenesis of diabetic vascular complications. Perit Dial Int 19 Suppl 2: S222-227, 1999
152. Shah SV: Light emission by isolated rat glomeruli in response to phorbol myristate acetate. J LabClin Med 98: 46-57, 1981
153. Miyanoshita A, Takahashi T, Endou H: Inhibitory effect of cyclic amp on phorbol ester-stimulated production of reactive oxygen metabolites in rat glomeruli. Biochem. Biophys. Res. Commun. 165: 519-525, 1989
154. Ha H, Endou H: Lipid peroxidation in isolated rat nephron segments. Am. J. Physiol. 263: F201-207, 1992
155. Ha H, Lee HB: Reactive oxygen species as glucose signaling molecules in mesangial cells cultured under high glucose. Kidney Int. Suppl. 77: S19-25, 2000
156. Hsieh TJ, Zhang SL, Filep JG, Tang SS, Ingelfinger JR, Chan JS: High glucose stimulates angiotensinogen gene expression via reactive oxygen species generation in rat kidney proximal tubular cells. Endocrinology 143: 2975-2985, 2002
157. Tomlinson DR: Mitogen-activated protein kinases as glucose transducers for diabetic complications. Diabetologia 42: 1271-1281, 1999
158. Berk BC: Redox signals that regulate the vascular response to injury. Thromb Haemost. 82: 810-817, 1999
159. Zhou G, Bao ZQ, Dixon JE: Components of a new human protein kinase signal transduction pathway. J. Biol. Chem. 270: 12665-12669, 1995
160. Strawn WB: Pathophysiological and clinical implications of AT(1) and AT(2) angiotensin II receptors in metabolic disorders: Hypercholesterolaemia and diabetes. Drugs 62: 31-41, 2002
161. Davi G, Chiarelli F, Santilli F, Pomilio M, Vigneri S, Falco A, Basili S, Ciabattoni G, Patrono C: Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: Role of interleukin-6 and disease duration. Circulation 107: 3199-3203, 2003
162. McFarlane SI, Kumar A, Sowers JR: Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am. J. Cardiol. 91: 30H-37H, 2003
163. Mezzano S, Droguett A, Burgos ME, Ardiles LG, Flores CA, Aros CA, Caorsi I, Vio CP, Ruiz-Ortega M, Egido J: Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy. Kidney Int. 64: Suppl 86 S64-70, 2003
164. Utimura R, Fujihara CK, Mattar AL, Malheiros DM, Noronha IL, Zatz R: Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int. 63: 209-216, 2003
165. Yozai K, Shikata K, Sasaki M, ToneA, Ohga S, Usui H, Okada S, Wada J, Nagase R, Ogawa D, Shikata Y, Makino H: Methotrexate prevents renal injury in experimental diabetic rats via anti-inflammatory actions. J. Am. Soc. Nephrol. 16: 3326-3338, 2005
166. Ogawa S, Mori T, Nako K, Kato T, Takeuchi K, Ito S: Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy. Hypertension 47: 699-705, 2006
167. de Vinuesa SG, Goicoechea M, Kanter J, Puerta M, Cachofeiro V, Lahera V, Gomez-Campdera F, Luno J: Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: Effects of angiotensin II blockade. J. Am. Soc. Nephrol. 17: S206-212, 2006
168. Egido J, Ruiz-Ortega M: Anti-inflammatory actions of quinapril. Cardiovasc. Drugs Ther. 2007
169. Wolkow PP, Niewczas MA, Perkins B, Ficociello LH, Lipinski B, Warram JH, Krolewski AS: Association of urinary inflammatory markers and renal decline in microalbuminuric type 1 diabetics. J.Am. Soc. Nephrol. 19: 789-797, 2008
170. Kagami S, Border WA, Miller DE, Noble NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J. Cuin. Invest. 93: 2431-2437, 1994
171. Border WA, Noble NA: Cytokines in kidney disease: The role of transforming growth factor-beta. Am. J. Kidney Dis 22: 105-113, 1993
172. Rao GN: Hydrogen peroxide induces complex formation of shc-grb2-sos with receptor tyrosine kinase and activates ras and extracellular signal-regulated protein kinases group of mitogen-activated protein kinases. Oncogene 13: 713-719, 1996
173. Yoshizumi M,Abe J, Haendeler J, Huang Q, Berk BC: Src and cas mediate JNK activation but not ERK1/2 and p38 kinases by reactive oxygen species. J.Biou. Chem. 275: 11706-11712, 2000
174. Suzaki Y, Yoshizumi M, Kagami S, Koyama AH, Taketani Y, Houchi H, Tsuchiya K, Takeda E, Tamaki T: Hydrogen peroxide stimulates c-src-mediated big mitogen-activated protein kinase 1 (BMK1) and the MEF2C signaling pathway in PC12 cells: Potential role in cell survival following oxidative insults. J. Biou. Chem. 277: 9614-9621, 2002
175. Suzaki Y, Yoshizumi M, Kagami S, NishiyamaA, Ozawa Y, Kyaw M, Izawa Y, Kanematsu Y, Tsuchiya K, Tamaki T: BMK1 is activated in glomeruli of diabetic rats and in mesangial cells by high glucose conditions. Kidney Int. 65: 1749-1760, 2004
176. Schreck R, Rieber P, Baeuerle PA: Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J. 10: 2247-2258, 1991
177. Perona R, Montaner S, Saniger L, Sanchez-Perez I, Bravo R, Lacal JC: Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins. Genes. Dev. 11: 463-475, 1997
178. Zhang SL, Tang SS, Chen X, Filep JG, Ingelfinger JR, Chan JS: High levels of glucose stimulate angiotensinogen gene expression via the p38 mitogen-activated protein kinase pathway in rat kidney proximal tubular cells. Endocrinology 141: 4637-4646, 2000
179. Li J, Brasier AR: Angiotensinogen gene activation by angiotensin II is mediated by the rel A (nuclear factor-kappaB p65) transcription factor: One mechanism for the renin angiotensin system positive feedback loop in hepatocytes. Mol. Endocrinol. 10: 252-264, 1996
180. Brinkmann MM, Glenn M, Rainbow L, Kieser A, Henke-Gendo C, Schulz TF: Activation of mitogen-activated protein kinase and NF-kappaB pathways by a kaposi's sarcoma-associated herpesvirus k15 membrane protein. J. Virol. 77: 9346-9358, 2003
181. Hoffmann E, Thiefes A, Buhrow D, Dittrich-Breiholz O, Schneider H, Resch K, Kracht M: Mek1-dependent delayed expression of fos-related antigen-1 counteracts c-fos and p65 NFkappaB-mediated interleukin-8 transcription in response to cytokines or growth factors. J. Biol. Chem. 280: 9706-9718, 2005
182. Zhang SL, Filep JG, Hohman TC, Tang SS, Ingelfinger JR, Chan JS: Molecular mechanisms of glucose action on angiotensinogen gene expression in rat proximal tubular cells. Kidney Int. 55: 454-464, 1999
183. Zhang SL, To C, Chen X, Filep JG, Tang SS, Ingelfinger JR, Chan JS: Essential role(s) of the intrarenal renin-angiotensin system in transforming growth factor-beta 1 gene expression and induction of hypertrophy of rat kidney proximal tubular cells in high glucose. J.Am. Soc. Nephrol. 13: 302-312, 2002
184. Zhang SL, Chen X, Hsieh TJ, Leclerc M, Henley N, Allidina A, Halle JP, Brunette MG, Filep JG, Tang SS, Ingelfinger JR, Chan JS: Hyperglycemia induces insulin resistance on angiotensinogen gene expression in diabetic rat kidney proximal tubular cells. J. Endocrinol. 172: 333-344, 2002
185. Zhang SL, Chen X, Wei CC, Filep JG, Tang SS, Ingelfinger JR, Chan JS: Insulin inhibits dexamethasone effect on angiotensinogen gene expression and induction of hypertrophy in rat kidney proximal tubular cells in high glucose. Endocrinology 143: 4627-4635, 2002
186. Hsieh TJ, Fustier P, Zhang SL, Filep JG, Tang SS, Ingelfinger JR, Fantus IG, Hamet P, Chan JS: High glucose stimulates angiotensinogen gene expression and cell hypertrophy via activation of the hexosamine biosynthesis pathway in rat kidney proximal tubular cells. Endocrinology 144: 4338-4349, 2003
187. Chen X, Zhang SL, Pang L, Filep JG, Tang SS, Ingelfinger JR, Chan JS: Characterization of a putative insulin-responsive element and its binding protein(s) in rat angiotensinogen gene promoter: Regulation by glucose and insulin. Endocrinology 142: 2577-2585, 2001
188. Hsieh TJ, Fustier P, Wei CC, Zhang SL, Filep JG, Tang SS, Ingelfinger JR, Fantus IG, Hamet P, Chan JS: Reactive oxygen species blockade and action of insulin on expression of angiotensinogen gene in proximal tubular cells. J.Endocrinol. 183: 535-550, 2004
189. Kobori H, Nishiyama A, Abe Y, Navar LG: Enhancement of intrarenal angiotensinogen in Dahl salt-sensitive rats on high salt diet. Hypertension 41: 592-597, 2003
190. Kobori H, Nishiyama A: Effects of tempol on renal angiotensinogen production in Dahl salt-sensitive rats. Biochem. Biophys. Res. Commu.n 315: 746-750, 2004
191. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest. 86: 1343-1346, 1990
192. Mizuiri S, Hemmi H, Kumanomidou H, Iwamoto M, Miyagi M, Sakai K, Aikawa A, Ohara T, Yamada K, Shimatake H, Hasegawa A: Angiotensin-converting enzyme (ACE) I/d genotype and renal ACE gene expression. Kidney Int. 60: 1124-1130, 2001
193. Marre M, Jeunemaitre X, Gallois Y, Rodier M, Chatellier G, Sert C, Dusselier L, Kahal Z, Chaillous L, Halimi S, Muller A, Sackmann H, Bauduceau B, Bled F, Passa P, Alhenc-Gelas F: Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la nephropathie diabetique (GENEDIAB) study group. J. Clin. Invest. 99: 1585-1595, 1997
194. Hadjadj S, Belloum R, Bouhanick B, Gallois Y, Guilloteau G, Chatellier G, Alhenc-Gelas F, Marre M: Prognostic value of angiotensin-I converting enzyme I/d polymorphism for nephropathy in type 1 diabetes mellitus: A prospective study. J.Am. Soc. Nephrol. 12: 541-549, 2001
195. Parving HH, Tarnow L, Rossing P: Genetics of diabetic nephropathy. J.Am. Soc. Nephrol. 7: 2509-2517, 1996
196. Ng DP, Tai BC, Koh D, Tan KW, Chia KS: Angiotensin-I converting enzyme insertion/deletion polymorphism and its association with diabetic nephropathy: A meta-analysis of studies reported between 1994 and 2004 and comprising 14,727 subjects. Diabetologia 48: 1008-1016, 2005
197. Osawa N, Koya D, Araki S, Uzu T, Tsunoda T, Kashiwagi A, Nakamura Y, Maeda S: Combinational effect of genes for the renin-angiotensin system in conferring susceptibility to diabetic nephropathy. J.Hum. Genet. 52: 143-151, 2007
198. So WY, Ma RC, Ozaki R, Tong PC, Ng MC, Ho CS, Lam CW, Chow CC, Chan WB, Kong AP, Chan JC: Angiotensin-converting enzyme (ACE) inhibition in type 2, diabetic patients--interaction with ACE insertion/deletion polymorphism. Kidney Int. 69: 1438-1443, 2006
199. Jacobsen PK, Tarnow L, Parving HH: Time to consider ACE insertion/deletion genotypes and individual renoprotective treatment in diabetic nephropathy? Kidney Int. 69: 1293-1295, 2006
200. Jacobsen P, Tarnow L, Carstensen B, Hovind P, Poirier O, Parving HH: Genetic variation in the renin-angiotensin system and progression of diabetic nephropathy. J.Am. Soc. Nephrol. 14: 2843-2850, 2003
201. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The captopril prevention project (CAPPP) randomised trial. Lancet 353: 611-616, 1999
202. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK prospective diabetes study group. BMJ 317: 713-720, 1998
203. Schmieder RE: Endothelial dysfunction: How can one intervene at the beginning of the cardiovascular continuum? J.Hypertens. Suppl. 24: S31-35, 2006
204. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P, Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study G: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 345: 870-878, 2001
205. Ruggenenti P, Fassi A, IlievaAP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G, Bergamo Nephrologic Diabetes Complications Trial I: Preventing microalbuminuria in type 2 diabetes. N. Engl. J. Med. 351: 1941-1951, 2004
206. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER, 3rd, Norris K, O'Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, ThornleyBrown D, Tisher CC, Toto RD, Wright JT, Jr., Xu S,African American Study of Kidney Disease and Hypertension Study G: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA 285: 2719-2728, 2001
207. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E,Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N.Eng.l J. Med. 345: 851-860, 2001
208. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J: Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N. Engl.J.Med. 351: 1952-1961, 2004
209. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsarinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S, investigators O: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 372: 547-553, 2008
210. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA 298: 2038-2047, 2007
211. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS: Regression of microalbuminuria in type 1 diabetes. NEngl. J.Med. 348: 2285-2293, 2003
212. Gould AB, Green D: Kinetics of the human renin and human substrate reaction. Cardiovasc. Res. 5: 86-89, 1971
213. Brasier AR, Li J: Mechanisms for inducible control of angiotensinogen gene transcription. Hypertension 27: 465-475, 1996
214. Ding Y, Davisson RL, Hardy DO, Zhu LJ, Merrill DC, Catterall JF, Sigmund CD: The kidney androgen-regulated protein promoter confers renal proximal tubule cell-specific and highly androgen-responsive expression on the human angiotensinogen gene in transgenic mice. JBiou Chem. 272: 28142-28148, 1997
215. Kimura S, Mullins JJ, Bunnemann B, Metzger R, Hilgenfeldt U, Zimmermann F, Jacob H, Fuxe K, Ganten D, Kaling M: High blood pressure in transgenic mice carrying the rat angiotensinogen gene. EMBO J. 11: 821-827, 1992
216. Fukamizu A, Sugimura K, Takimoto E, Sugiyama F, Seo MS, Takahashi S, Hatae T, Kajiwara N, Yagami K, Murakami K: Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes. J. Biou. Chem. 268: 11617-11621, 1993
217. Bohlender J, Menard J, Ganten D, Luft FC: Angiotensinogen concentrations and renin clearance: Implications for blood pressure regulation. Hypertension 35: 780-786, 2000
218. Smithies O: Theodore cooper memorial lecture. A mouse view of hypertension. Hypertension 30: 1318-1324, 1997
219. Merrill DC, Thompson MW, Carney CL, Granwehr BP, Schlager G, Robillard JE, Sigmund CD: Chronic hypertension and altered baroreflex responses in transgenic mice containing the human renin and human angiotensinogen genes. J. Cuin. Invest. 97: 1047-1055, 1996
220. Kobori H, Ozawa Y, Satou R, Katsurada A, Miyata K, Ohashi N, Hase N, Suzaki Y,Sigmund CD, Navar LG: Kidney-specific enhancement of ANG II stimulates endogenous intrarenal angiotensinogen in gene-targeted mice. Am J Physiol Renal Physiol 293: F938-F945, 2007
221. Sachetelli S, Liu Q, Zhang SL, Liu F, Hsieh TJ, Brezniceanu ML, Guo DF, Filep JG, Ingelfinger JR, Sigmund CD, Hamet P, Chan JS: RAS blockade decreases blood pressure and proteinuria in transgenic mice overexpressing rat angiotensinogen gene in the kidney. Kidney Int. 69: 1016-1023, 2006
222. Lavoie JL, Lake-Bruse KD, Sigmund CD: Increased blood pressure in transgenic mice expressing both human renin and angiotensinogen in the renal proximal tubule. Am. J. Physiol. Renal. Physiol. 286: F965-971, 2004
223. Smithies O, Kim HS: Targeted gene duplication and disruption for analyzing quantitative genetic traits in mice. Proc. Natl. Acad. Sci. U S A 91: 3612-3615, 1994
224. Kim HS, Krege JH, Kluckman KD, Hagaman JR, Hodgin JB, Best CF, Jennette JC, Coffman TM, Maeda N, Smithies O: Genetic control of blood pressure and the angiotensinogen locus. Proc. Natl. Acad. Sci. U S A 92: 2735-2739, 1995
225. Inoue I, Nakajima T, Williams CS, Quackenbush J, Puryear R, Powers M, Cheng T, Ludwig EH, Sharma AM, Hata A, Jeunemaitre X, Lalouel JM: A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J. Clin. Invest. 99: 1786-1797, 1997
226. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A, Hunt SC, Hopkins PN, Williams RR, Lalouel JM: Molecular basis of human hypertension: Role of angiotensinogen. Cell 71: 169-180, 1992
227. Zhao YY, Zhou J, Narayanan CS, Cui Y, Kumar A: Role of C/A polymorphism at-20 on the expression of human angiotensinogen gene. Hypertension 33: 108-115, 1999
228. Ishigami T, Umemura S, Tamura K, Hibi K, Nyui N, Kihara M, Yabana M, Watanabe Y, Sumida Y, Nagahara T, Ochiai H, Ishii M: Essential hypertension and 5' upstream core promoter region of human angiotensinogen gene. Hypertension 30: 1325-1330, 1997
229. Schunkert H, Ingelfinger JR, Jacob H, Jackson B, Bouyounes B, Dzau VJ: Reciprocal feedback regulation of kidney angiotensinogen and renin mRNA expressions by angiotensin II. Am. J. Physiol. 263: E863-E869, 1992
230. Kobori H, Prieto-Carrasquero MC, Ozawa Y, Navar LG: AT1 receptor mediated augmentation of intrarenal angiotensinogen in angiotensin II-dependent hypertension. Hypertension 43: 1126-1132, 2004
231. Kobori H, Nishiyama A, Harrison-Bernard LM, Navar LG: Urinary angiotensinogen as an indicator of intrarenal angiotensin status in hypertension. Hypertension 41: 42-49, 2003
232. Kobori H, Harrison-Bernard LM, Navar LG: Urinary excretion of angiotensinogen reflects intrarenal angiotensinogen production. Kidney Int. 61: 579-585, 2002
233. Kobori H, Harrison-Bernard LM, Navar LG: Enhancement of angiotensinogen expression in angiotensin II-dependent hypertension. Hypertension 37: 1329-1335, 2001
234. Kobori H, Ozawa Y, Suzaki Y, Nishiyama A: Enhanced intrarenal angiotensinogen contributes to early renal injury in spontaneously hypertensive rats. JAm Soc Nephrol 16: 2073-2080, 2005
235. Singh R, Singh AK, Leehey DJ: A novel mechanism for angiotensin II formation in streptozotocin-diabetic rat glomeruli. Am. J. Physiol. Renal. Physiol. 288: F1183-1190, 2005
236. Leehey DJ, Singh AK, Bast JP, Sethupathi P, Singh R: Glomerular renin angiotensin system in streptozotocin diabetic and Zucker diabetic fatty rats. Transl. Res. 151: 208-216, 2008
237. Kobori H, Katsurada A, Ozawa Y, Satou R, Miyata K, Hase N, Suzaki Y, Shoji T: Enhanced intrarenal oxidative stress and angiotensinogen in IgA nephropathy patients. Biochem Biophys. Res. Commun. 358: 156-163, 2007
238. Takamatsu M, Urushihara M, Kondo S, Shimizu M, Morioka T, Oite T, Kobori H, Kagami S: Glomerular angiotensinogen protein is enhanced in pediatric IgA nephropathy. Pediat. Nephrol. 23: 1257-1267, 2008
239. Kobori H, Ozawa Y, Suzaki Y, Prieto-Carrasquero MC, NishiyamaA, Shoji T, Cohen EP, Navar LG: Young scholars award lecture: Intratubular angiotensinogen in hypertension and kidney diseases. Am. J. Hypertens. 19: 541-550, 2006
240. Katsurada A, Hagiwara Y, Miyashita K, Satou R, Miyata K, Ohashi N, Navar LG, Kobori H: Novel sandwich ELISA for human angiotensinogen. Am. J. Physiol. Renal Physiol. 293: F956-F960, 2007
241. Yamamoto T, Nakagawa T, Suzuki H, Ohashi N, Fukasawa H, Fujigaki Y, Kato A, Nakamura Y, Suzuki F, Hishida A: Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease. Jam. Soc. Nephrol. 18: 1558-1565, 2007
242. Kobori H, Ohashi N, Katsurada A, Miyata K, Satou R, Saito T, Yamamoto T: Urinary angiotensinogen as a potential biomarker of severity of chronic kidney diseases. Jam. Soc. Hypertens 2: 349-354, 2008
243. Kobori H, Alper AB, Shenava R, Katsurada A, Saito T, Ohashi N, Urushihara M, Miyata K, Satou R, Hamm LL, Navar LG: Urinary angiotensinogen as a novel biomarker of the intrarenal renin-angiotensin system status in hypertensive patients. Hypertension 53: 344-350, 2009
244. Ogawa S, Kobori H, Ohashi N, Urushihara M, NishiyamaA, Mori T, Ishizuka T, Nako K, Ito S: Angiotensin II type 1 receptor blockers reduce urinary angiotensinogen excretion and the levels of urinary markers of oxidative stress and inflammation in patients with type 2 diabetic nephropathy. Biomark Insights 4: 97-102, 2009
245. Saito T, Urushihara M, Kotani Y, Kagami S, Kobori H: Increased urinary angiotensinogen is precedent to increased urinary albumin in patients with type 1 diabetes. Am. J. Med. Sci. 338: 478-480, 2009